Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SAGE Sage Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: SAGE
Price (delayed)
$6.61
Market cap
$413.92M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.8
Enterprise value
$379.1M
Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing
Highlights
Sage Therapeutics's EPS has increased by 31% YoY and by 12% from the previous quarter
The net income has increased by 30% year-on-year and by 12% since the previous quarter
The company's gross profit has shrunk by 56% YoY but it rose by 21% QoQ
The revenue has decreased by 48% YoY but it has increased by 15% from the previous quarter
SAGE's equity is down by 42% YoY and by 12% from the previous quarter
Key stats
What are the main financial stats of SAGE
Market
Valuations
Earnings
Shares outstanding
62.62M
Market cap
$413.92M
Enterprise value
$379.1M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.99
Price to sales (P/S)
8.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8
Revenue
$47.4M
Gross profit
$38.58M
Operating income
-$382.15M
Net income
-$354.4M
EBIT
-$354.4M
EBITDA
-$353.59M
Free cash flow
-$311.09M
Per share
Balance sheet
Liquidity
EPS
-$5.8
EPS diluted
-$5.8
Free cash flow per share
-$5.03
Book value per share
$6.67
Revenue per share
$0.77
TBVPS
$7.59
Total assets
$469.67M
Total liabilities
$59.82M
Debt
$11.86M
Equity
$409.85M
Working capital
$404.7M
Debt to equity
0.03
Current ratio
9.13
Quick ratio
8.76
Net debt/EBITDA
0.1
Margins
Efficiency
Dividend
EBITDA margin
-745.9%
Gross margin
81.4%
Net margin
-747.6%
Operating margin
-806.2%
Return on assets
-60.7%
Return on equity
-69%
Return on invested capital
-79.2%
Return on capital employed
-84.4%
Return on sales
-747.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SAGE stock price
How has the Sage Therapeutics stock price performed over time
Intraday
-2.79%
1 week
0%
1 month
-13.93%
1 year
-45.37%
YTD
21.73%
QTD
-16.86%
Financial performance
How have Sage Therapeutics's revenue and profit performed over time
Revenue
$47.4M
Gross profit
$38.58M
Operating income
-$382.15M
Net income
-$354.4M
Gross margin
81.4%
Net margin
-747.6%
The company's gross profit has shrunk by 56% YoY but it rose by 21% QoQ
The revenue has decreased by 48% YoY but it has increased by 15% from the previous quarter
Sage Therapeutics's operating margin has decreased by 35% YoY but it has increased by 23% QoQ
The company's net margin fell by 35% YoY but it rose by 23% QoQ
Price vs fundamentals
How does SAGE's price correlate with its fundamentals
Growth
What is Sage Therapeutics's growth rate over time
Valuation
What is Sage Therapeutics stock price valuation
P/E
N/A
P/B
0.99
P/S
8.63
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8
Sage Therapeutics's EPS has increased by 31% YoY and by 12% from the previous quarter
The P/B is 45% less than the 5-year quarterly average of 1.8 but 10% more than the last 4 quarters average of 0.9
SAGE's equity is down by 42% YoY and by 12% from the previous quarter
SAGE's P/S is 94% below its 5-year quarterly average of 154.2 but 18% above its last 4 quarters average of 7.3
The revenue has decreased by 48% YoY but it has increased by 15% from the previous quarter
Efficiency
How efficient is Sage Therapeutics business performance
Sage Therapeutics's ROS has decreased by 35% YoY but it has increased by 23% from the previous quarter
Sage Therapeutics's ROE has decreased by 13% YoY
SAGE's ROA is down by 11% year-on-year
The ROIC has contracted by 11% YoY but it has grown by 4.2% from the previous quarter
Dividends
What is SAGE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SAGE.
Financial health
How did Sage Therapeutics financials performed over time
The total assets has declined by 39% year-on-year and by 14% since the previous quarter
Sage Therapeutics's total liabilities has decreased by 27% QoQ and by 3.2% YoY
The company's debt is 97% lower than its equity
SAGE's equity is down by 42% YoY and by 12% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.